Key result
TAK1-NLK pathway drives C/EBP activation via kinase-independent stabilization of ATF5.
Why the study?
The mechanism by which IL-1β propagates a signal that activates C/EBP has remained elusive.
The study identifies the TAK1-NLK pathway as a novel regulator of IL-1β-triggered C/EBP activation through the stabilization of ATF5.
Extends preclinical insight into IL-1β signaling; hypothesis-generating for cardiovascular inflammation with no immediate clinical implications.
Interleukin-1β (IL-1β) is a key proinflammatory cytokine that initiates several signaling cascades, including those involving CCAAT/enhancer binding proteins (C/EBPs). The mechanism by which IL-1β propagates a signal that activates C/EBP has remained elusive. Nemo-like kinase (NLK) is a mitogen-activated protein kinase (MAPK)-like kinase associated with many pathways and phenotypes that are not yet well understood. Using a luciferase reporter screen, we found that IL-1β-induced C/EBP activation was positively regulated by NLK. Overexpression of NLK activated C/EBP and potentiated IL-1β-triggered C/EBP activation, whereas knockdown or knockout of NLK had the opposite effect. NLK interacted with activating transcription factor 5 (ATF5) and inhibited the proteasome-dependent degradation of ATF5 in a kinase-independent manner. Consistently, NLK deficiency resulted in decreased levels of ATF5. NLK cooperated with ATF5 to activate C/EBP, whereas NLK could not activate C/EBP upon knockdown of ATF5. Moreover, TAK1, a downstream effector of IL-1β that acts upstream of NLK, mimicked the ability of NLK to stabilize ATF5 and activate C/EBP. Thus, our findings reveal the TAK1-NLK pathway as a novel regulator of basal or IL-1β-triggered C/EBP activation though stabilization of ATF5.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) studied this question. NLK overexpression or knockdown/knockout vs. Control was evaluated on C/EBP activation and ATF5 stabilization. The TAK1-NLK pathway positively regulates basal and IL-1β-triggered C/EBP activation through the kinase-independent stabilization of ATF5.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: